Refractory or Recurrent CD30+ Hematologic Malignancies
1 clinical trials · Condition
◉ Watch Refractory or Recurrent CD30+ Hematologic Malignancies
| Record | Firm | Date |
|---|---|---|
| A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. (NCT03894150) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2019-04-11 |
Track Refractory or Recurrent CD30+ Hematologic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.